EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Recurrent Event Analyses in Patients Receiving Maintenance Dialysis and the Effect of Higher- Versus Lower-Dose Chronic Intravenous Iron Therapy: A Report Focusing on Heart Failure Events from the PIVOTAL Trial

Stefan D Anker, Michele Robertson, John J V McMurray, Pardeep S Jhund, Claire White, Chante Reid, Sunil Bhandari, Ken Farrington, Philip A Kalra, Khawaja M Talha, Patrick B Mark, Charles R V Tomson und 4 weitere

European Journal of Heart Failure · 2025

DOI: 10.1002/ejhf.3670 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Stefan D Anker und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universi…. Hauptthemen laut MEDLINE: Heart Failure, Renal Dialysis, Kidney Failure, Chronic, Ferric Compounds. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Kidney Research UK, Vifor Fresenius Medical Care Renal Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

In the PIVOTAL trial, a proactive high-dose regimen of intravenous iron sucrose, compared to a lower-dose reactive regimen, reduced the risk of first and recurrent events of the primary endpoint in haemodialysis patients. We present the various approaches of recurrent event analyses for the primary endpoint and for the composite of cardiovascular (CV) death or heart failure hospitalization and their non-fatal components. Methods and results Patients were randomized to a proactive maintenance dose of iron sucrose (average 264 mg/month) or a reactive treatment regimen (average 145 mg/month). We compared the results of time-to-first event analyses with recurrent event analysis using the negative binomial model and methods proposed by Wei–Lin–Weissfeld, Andersen and Gill, Lin, Wei, Yang and Ying [LWYY], Mao and Lin, and Rondeau and colleagues. The 2141 haemodialysis patients were followed for a median of 2.1 years and experienced 936 primary recurrent events, which is 42% higher than the number of 658 first events. Proactive regimen patients had 429 primary events (19.4/100 patient-years) compared with 507 events in the reactive regimen patients (24.6/100 patient-years) (rate ratio 0.77, 95% confidence interval [CI] 0.66–0.92, p = 0.0027, LWYY). Recurrent events were also reduced in the proactive regimen for the composite of CV mortality and heart failure hospitalizations (rate ratio 0.73, 95% CI 0.56–0.93, p = 0.013). Recurrent event analyses based on other approaches were very similar to those given above based on the method of LWYY.

Conclusion

A higher dose of chronic intravenous iron therapy compared to a lower dose substantially reduced the total burden of important recurrent events of death and CV disease in patients with end-stage kidney disease receiving maintenance haemodialysis therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart FailureRenal DialysisKidney Failure, ChronicFerric CompoundsHematinicsGlucaric AcidHumansFemaleMaleMiddle AgedAgedRecurrenceFerric Oxide, SaccharatedDose-Response Relationship, DrugHospitalizationTreatment OutcomeAdministration, Intravenous

Stichwörter der Autor:innen

Chronic kidney diseaseClinical trialIron deficiencyRecurrent events

Substanzen

Ferric Oxide, SaccharatedFerric CompoundsHematinicsGlucaric Acid

Autor:innen und Institutionen

  • Department of Cardiology (CVK) of German Heart Center Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
  • Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK.
  • BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
  • Department of Renal Medicine, King's College Hospital, London, UK.
  • Hull University Teaching Hospitals NHS Trust and Hull York Medical School, Hull, UK.
  • Lister Hospital, Stevenage, UK.

Förderung

  • Kidney Research UK
  • Vifor Fresenius Medical Care Renal Pharma

Zitieren

APA

Anker, S. D., Robertson, M., McMurray, J. J. V., Jhund, P. S., White, C., Reid, C., Bhandari, S., Farrington, K., Kalra, P. A., Talha, K. M., Mark, P. B., Tomson, C. R. V., Wheeler, D. C., Winearls, C. G., Macdougall, I. C., & Ford, I. (2025). Recurrent Event Analyses in Patients Receiving Maintenance Dialysis and the Effect of Higher- Versus Lower-Dose Chronic Intravenous Iron Therapy: A Report Focusing on Heart Failure Events from the PIVOTAL Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.3670

Vancouver

Anker SD, Robertson M, McMurray JJV, Jhund PS, White C, Reid C, et al. Recurrent Event Analyses in Patients Receiving Maintenance Dialysis and the Effect of Higher- Versus Lower-Dose Chronic Intravenous Iron Therapy: A Report Focusing on Heart Failure Events from the PIVOTAL Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.3670

BibTeX
@article{Anker2025,
  author = {Anker, Stefan D and Robertson, Michele and McMurray, John J V and Jhund, Pardeep S and White, Claire and Reid, Chante and Bhandari, Sunil and Farrington, Ken and Kalra, Philip A and Talha, Khawaja M and Mark, Patrick B and Tomson, Charles R V and Wheeler, David C and Winearls, Chris G and Macdougall, Iain C and Ford, Ian},
  title = {Recurrent Event Analyses in Patients Receiving Maintenance Dialysis and the Effect of Higher- Versus Lower-Dose Chronic Intravenous Iron Therapy: A Report Focusing on Heart Failure Events from the PIVOTAL Trial},
  journal = {European Journal of Heart Failure},
  year = {2025},
  doi = {10.1002/ejhf.3670}
}
Kostenlos starten →